Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 6/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1214836 | 0.88 | ELANE (0.64) | ELANEPTGER4MAPK8MCL1 | |
| SCHEMBL2433523 | 0.83 | PTGER4 (0.68) | ELANEPTGER4CNR1CNR2ALOX15 | |
| SCHEMBL29121525 | 0.82 | ELANE (0.60) | ELANEPTGER4L3MBTL1 | |
| SCHEMBL4317819 | 0.81 | PIK3R1 (0.53) | PTGER4PTGS2PIK3R1PIK3CACNR1 | |
| SCHEMBL22914198 | 0.81 | PTGER4 (0.48) | PTGER4MAPK8MCL1PTGS2PIK3R1 | |
| SCHEMBL21811367 | 0.80 | PTGER4 (0.53) | PTGER4MAPK8PTGS2PIK3R1PIK3CA | |
| SCHEMBL30902962 | 0.80 | PTGER4 (0.53) | PTGER4MAPK8PTGS2PIK3R1PIK3CA | |
| SCHEMBL30676419 | 0.80 | ELANE (0.58) | ELANEPTGER4L3MBTL1 | |
| SCHEMBL29122000 | 0.80 | ELANE (0.58) | ELANEPTGER4L3MBTL1 | |
| SCHEMBL24149413 | 0.80 | PIK3R1 (0.49) | PTGER4MAPK8PTGS2PIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2021262684-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731953-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | ELANE 1923/4885PTGER4 4554/4885MAPK8 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.